miR-206 inhibits liver cancer stem cell expansion by regulating EGFR expression

References

• El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–1127.
   PubMed Web of Science ®Google Scholar
• Laursen L. A preventable cancer. Nature. 2014;516(7529):S2–3.
   PubMedGoogle Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–1255.
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002;35:S72–78.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Worns MA, Galle PR. HCC therapies–lessons learned. Nat Rev Gastroenterol Hepatol. 2014;11(7):447–452.
   PubMed Web of Science ®Google Scholar
• Shah C, Mramba LK, Bishnoi R, et al. Survival differences among patients with hepatocellular carcinoma based on the stage of disease and therapy received: pre and post sorafenib era. J Gastrointest Oncol. 2017;8:789–798.
   PubMed Web of Science ®Google Scholar
• Han T, Xiang DM, Sun W, et al. PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients. J Hepatol. 2015;63:651–660.
   PubMed Web of Science ®Google Scholar
• Miyajima A, Tanaka M, Itoh T. Stem/progenitor cells in liver development, homeostasis, regeneration, and reprogramming. Cell Stem Cell. 2014;14(5):561–574.
   PubMed Web of Science ®Google Scholar
• Li XF, Chen C, Xiang DM, et al. Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance. Hepatology. 2017;66(6):1934–1951.
   Web of Science ®Google Scholar
• Lee TK, Castilho A, Cheung VC, et al. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell. 2011;9(1):50–63.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136(3):1012–1024.
   PubMed Web of Science ®Google Scholar
• Zhou G, Latchoumanin O, Bagdesar M, et al. Aptamer-based therapeutic approaches to target cancer stem cells. Theranostics. 2017;7(16):3948–3961.
   PubMed Web of Science ®Google Scholar
• DeSano JT, Xu L. MicroRNA regulation of cancer stem cells and therapeutic implications. Aaps J. 2009;11(4):682–692.
   PubMed Web of Science ®Google Scholar
• Bayoumi AS, Sayed A, Broskova Z, et al. Crosstalk between long noncoding RNAs and microRNAs in health and disease. Int J Mol Sci. 2016;17(3):356. .
   PubMed Web of Science ®Google Scholar
• Nucera S, Giustacchini A, Boccalatte F, et al. miRNA-126 orchestrates an oncogenic program in B cell precursor acute lymphoblastic leukemia. Cancer Cell. 2016;29(6):905–921.
   PubMed Web of Science ®Google Scholar
• Wu J, Yuan P, Mao Q, et al. RETRACTED: miR-613 inhibits proliferation and invasion of breast cancer cell via VEGFA. Biochem Biophys Res Commun. 2016;478(1):274–278.
   PubMed Web of Science ®Google Scholar
• Li L, Tang J, Zhang B, et al. Epigenetic modification of MiR-429 promotes liver tumour-initiating cell properties by targeting Rb binding protein 4. Gut. 2015;64(1):156–167.
   PubMed Web of Science ®Google Scholar
• Pan JY, Sun CC, Bi ZY, et al. miR-206/133b cluster: a weapon against lung cancer? Mol Ther Nucleic Acids. 2017;8:442–449.
   PubMedGoogle Scholar
• Zheng Z, Yan D, Chen X, et al. MicroRNA-206: effective inhibition of gastric cancer progression through the c-Met pathway. PLoS One. 2015;10(7):e0128751.
   PubMed Web of Science ®Google Scholar
• Xiang DM, Sun W, Ning BF, et al. The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis. Gut. 2018;67(9):1704–1715.
   Web of Science ®Google Scholar
• Xiang D, Cheng Z, Liu H, et al. Shp2 promotes liver cancer stem cell expansion by augmenting beta-catenin signaling and predicts chemotherapeutic response of patients. Hepatology. 2017;65(5):1566–1580.
   PubMed Web of Science ®Google Scholar
• Deng M, Qin Y, Chen X, et al. MiR-206 inhibits proliferation, migration, and invasion of gastric cancer cells by targeting the MUC1 gene. Onco Targets Ther. 2019;12:849–859.
   PubMed Web of Science ®Google Scholar
• Heinemann FG, Tolkach Y, Deng M, et al. Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma. Clin Epigenetics. 2018;10(1):11.
   PubMed Web of Science ®Google Scholar
• Liu F, Yin R, Chen X, et al. Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma. Biomed Pharmacother. 2019;114:108605.
   PubMed Web of Science ®Google Scholar
• Ma S, Lee TK, Zheng BJ, et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008;27(12):1749–1758.
   PubMed Web of Science ®Google Scholar
• Hassan S, Esch A, Liby T, et al. Pathway-enriched gene signature associated with 53Bp1 response to PARP inhibition in triple-negative breast cancer. Mol Cancer Ther. 2017;16(12):2892–2901.
   PubMed Web of Science ®Google Scholar
• Choi BH, Ryu DY, Ryoo IG, et al. NFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells. Oncotarget. 2017;8(63):107188–107205.
   PubMedGoogle Scholar
• Zou B, Lee VHF, Yan H. Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis. BMC Bioinformatics. 2018;19:88.
   PubMed Web of Science ®Google Scholar
• Nishida N, Kudo M. Oncogenic signal and tumor microenvironment in hepatocellular carcinoma. Oncology. 2017;93(Suppl 1):160–164.
   PubMed Web of Science ®Google Scholar
• Park YK, Song SK, Kim BW, et al. Prognostic significance of microvascular invasion in tumor stage for hepatocellular carcinoma. World J Surg Oncol. 2017;15:225.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Lin M, Jiang X, et al. The recent advances on liver cancer stem cells: biomarkers, separation, and therapy. Anal Cell Pathol (Amst). 2017;2017:5108653.
   PubMedGoogle Scholar
• Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769–773.
   PubMed Web of Science ®Google Scholar
• Pan BL, Tong ZW, Wu L, et al. Effects of microRNA-206 on osteosarcoma cell proliferation, apoptosis, migration and invasion by targeting ANXA2 through the AKT signaling pathway. Cell Physiol Biochem. 2018;45(4):1410–1422. .
   PubMedGoogle Scholar
• Xiang DM, Sun W, Zhou T, et al. Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance. Gut. 2019;68(10):1858–1871.
   Web of Science ®Google Scholar
• Yang W, Wang C, Lin Y, et al. OV6(+) tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma. J Hepatol. 2012;57(3):613–620.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002;29(1):27–36.
   PubMed Web of Science ®Google Scholar
• Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer. 1996;32A(12):2070–2074.
   PubMed Web of Science ®Google Scholar
• Ethier SP. Signal transduction pathways: the molecular basis for targeted therapies. Semin Radiat Oncol. 2002;12(3):3–10.
   PubMed Web of Science ®Google Scholar
• Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005;23(11):2445–2459.
   PubMed Web of Science ®Google Scholar